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 3 
Abstract 
 
Cystic Fibrosis (CF) is the most frequently inherited complication among Caucasians 
today, affecting 30,000 people in the U.S. alone. The major cause of mortality within CF 
patients is the development of chronic persistent infections by the opportunistic pathogen 
Pseudomonas aeruginosa. Typical antibacterial defense mechanisms used within healthy 
individuals such as Cationic Antimicrobial Peptides (CAMPs) are inhibited within CF 
patients. The inhibition is mediated by modification of the bacterial surface in the specific 
environment of the CF lung, namely: the covalent addition of Ara4NH4+ to Lipid A. This 
unique Lipid A modification utilized by P. aeruginosa within CF patients has been 
proven to establish a resistance against both CAMPs and last resort antibiotics such as 
Polymyxins. Abolishing this Lipid A modification would help control the pulmonary 
infections and thus holds significant promise as a means of extending the life expectancy 
and improving the quality of life of CF patients. The enzymes responsible for mediating a 
resistance against CAMPs are encoded by the seven-enzyme operon ArnBCADTEF. 
Here, I show that ArnD, an essential enzyme within the biosynthetic pathway, is capable 
of converting Undecaprenyl Phosphate-L-Ara4N-formyl to a novel species, which I 
propose is the deformylated intermediate Undecaprenyl Phosphate-L-Ara4N. I further 
show that the catalytic activity of ArnD is dependent on residues D43 and H233 as 
mutation of these residues dramatically reduces ArnD activity. This is consistent with 
ArnD catalyzing the deformylation reaction by a mechanism analogous to that of 
polysaccharide deacetylases, a family of metal dependent hydrolases. This would 
establish ArnD as the essential deformylase within the reaction pathway that leads to 
Lipid A Ara4NH4+ biosynthesis and bacterial resistance to CAMPs and clinical 
antibiotics of the same family such as Polymyxin B and Colistin. 
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Introduction: 
 
Disease Background 
 
CF is a genetic disease affecting approximately 30,000 people in the U.S. alone, and 
70,000 worldwide [9]. CF is one of the most prevalent lethal hereditary disorders with a 
predicted median age of survival for a person with CF in the late 30s [9]. It is the most 
common inherited disorder amongst Caucasians; with an estimated 1 in 29 Caucasian 
Americans carrying the CF allele, and 1,000 new cases diagnosed annually [10]. 
 
In CF, homeostasis is upset due to a defect in the cystic fibrosis transmembrane-
conductance regulator (CFTR) gene. This leads to a characteristic accumulation of thick 
mucus in the lungs, pancreatic ducts, and male reproductive tract. Within this 
environment, opportunistic pathogens such as Pseudomonas aeruginosa express genes 
that mediate resistance to the host immune system. This leads to bacterial colonization, 
bacterial overgrowth, and chronic, tissue-destructive inflammation [11]. These persistent 
infections are the main cause of mortality in CF. 
 
This project is focused on understanding the resistance mechanisms that help 
bacteria colonize the CF lung. 
 
Since CF is an autosomal recessive disease, an 
individual must have two copies of a mutated 
CFTR gene to express the disease phenotype. 
Thus, those affected by the disease are 
homozygous for mutations in the CFTR gene, 
while heterozygous individuals are relatively 
unaffected carriers.  Approximately 70% of all 
CF patients carry the ∆508F mutation: a three 
base pair deletion in the CFTR gene (Figure 
1)[4]. However, a small subset of patients carry 
the G551D mutation. In this case, the disease 
can be treated with ivacaftor ® (Vertex), a 
recently introduced CFTR inhibitor. This 
treatment method targets the CFTR gene 
mutation directly. On the other hand, there is no 
CFTR-targeted treatment currently available for 
the majority of the CF patient population. 
Therefore, it is important to develop treatments 
for the persistent infections that account for the 
majority of mortality associated with CF. 
 
Homozygous CFTR-mutants experience a defective transmembrane chloride ion channel 
resulting in an electrolyte imbalance. A normal sodium and chloride ion balance is 
needed to produce the thin mucus layer easily removed from the epithelial lining within 
wild-type (WT) individuals. The electrolyte imbalance in CF patients results in a 
Figur e 1: The ∆F508 deletion is the most 
common cause of cystic fibrosis. Ile507 
remains unchanged because of degenerate 
code: ATC and ATT both code for 
isoleucine. Figure taken from [4] 
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dehydrated mucus that is difficult to remove. This stationary sticky mucus layer is prone 
to colonization by Gram-negative bacteria, developing the chronic persistent infections 
that, as mentioned before, are the major cause of morbidity and mortality in CF [4]. 
 
Specifically, infections with Pseudomonas aeruginosa have been strongly correlated with 
CF mortality; approximately 80% of CF patients between the ages of 25 and 34 are 
infected with P. aeruginosa [8, 12]. These persistent infections in CF patients lead to 
inflammation, declining lung function, and death. Due to the fact that P. aeruginosa is the 
most frequently reported pathogen among CF patients, controlling these pulmonary 
infections holds significant promise as a means of extending the longevity and improving 
the quality of life of CF patients [9]. 
 
Numerous antimicrobial mechanisms act in unison to protect the healthy lung from 
infection within WT individuals, effectively forming a host defense system [13]. One 
way healthy individuals eliminate bacteria, including P. aeruginosa, from their bronchi is 
mucociliary clearance [14]. This mechanism encompasses the coordinated movement of 
cilia attached to the respiratory epithelium towards the pharynx. This synchronized 
movement carries microorganisms up towards the throat to be swallowed into the 
digestive environment of the stomach. Bacteria left behind by mucociliary clearance face 
a series of rapid-acting defense mechanisms provided by the innate immune response. 
Phagocytic cells are released from proximate lymph nodes such as the tonsils, and a 
number of Cationic Antimicrobial Peptides (CAMPs) are secreted, primarily from the 
airway epithelium. 
 
The defensive mechanisms typically active within a healthy lung are inhibited within the 
CF lung. As a result of the mutated CFTR gene, mucociliary clearance is repressed due to 
the dehydrated viscous nature of the mucus layer covering the airway epithelium. This 
allows for bacteria to colonize the airway epithelium fluid layer. Once established, P. 
aeruginosa adopts a mucoid phenotype, overproducing alginate and forming a biofilm. 
This biofilm is highly sticky and makes it difficult for phagocytic cells and antibiotics to 
penetrate [15]. Furthermore, the effectiveness of CAMPs against P. aeruginosa appears 
to be reduced in CF patients. The loss of activity of CAMPs is explained by two specific 
alterations in the CF lung. First, there is an increased salt concentration in the airway 
surface fluid that reduces their effectiveness [13]. Second, and more specifically, a 
particular modification on the bacterial surface of P. aeruginosa mediates resistance to 
the CAMPs. 
 
 
 
 
 
 
 
 
 
 
 7 
Cationic Antimicrobial Peptides (CAMPs) 
 
CAMPs are found in all kingdoms of life. In mammals, they are produced in large 
quantities at sites of infection, such as the lungs, which are consistently bombarded by 
bacteria with nearly every breath. These peptides have broad-spectrum antibacterial, 
antifungal, antiviral and antiprotozoan properties [16]. Structural properties of CAMPs 
vary considerably, with a few common features. All CAMPs are encoded as larger 
precursors and subsequently modified [17], they are relatively small proteins, 12-50 
amino acids, and are all amphipathic but positively charged. This positively charged 
feature of CAMPs mediates the electrostatic interaction the peptides have with the 
negatively charged microbial outer membrane, in the case of Gram-negative bacteria.  
 
CAMPs target a fundamental difference between microbes and multicellular animals: the 
structure of their membranes. This distinguishing quality allows for CAMPs to target 
infectious microbes rather than host organism cells. This characterization of a foreign 
species can be more easily understood by looking more closely at bacterial targets, 
specifically Gram-negative bacteria.  
 
Both Gram-positive and Gram-negative bacterial membranes have a peptidoglycan cell 
wall and a phospholipid bilayer with membrane-spanning proteins. Gram-negative 
bacteria, however, have an additional unique outer membrane (Figure 2). The Gram-
negative outer membrane is an asymmetric bilayer that consists of phospholipids on the 
inner leaflet and Lipid A, the lipid anchor region of Lipo-Poly-Saccharide (LPS), on the 
outer leaflet [18]. Lipid A, or endotoxin, is recognized by the innate immune system. The 
outer leaflet faces the external environment and is rich in negatively charged phosphate 
headgroups [6]. This is in contrast to animal and plant membranes where most lipids 
facing the external environment are neutral, and negatively charged headgroups are 
Figur e 2: Cartoon Model of Gram-negative bacterial 
membrane. Contains inner and outer membrane 
separated by peptidoglycan wall. LPS and Lipid A are 
anchored to outer leaflet of outer membrane. Image 
taken from [5]. 
Figur e 3: Cartoon Model depicting the how CAMPs 
differentiate between animal cell membranes and 
bacterial cell membranes. CAMPs bind negatively 
charged membranes with higher affinity. Image taken 
from [6]. 
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localized to the inner leaflet. The different electrostatic properties of animal membranes 
allow for CAMPs to properly target microbes for destruction (Figure 3) [6]. Another 
feature, which protects animal cells, is cholesterol, which is present in animal membranes 
but is excluded from bacterial membranes. Cholesterol mitigates the activity of CAMPs 
either by stabilizing the non-microbial membrane or by interacting with the peptide 
directly [19]. 
 
CAMPs destroy microbes via permeabilization of their membranes. The Shai-Matsuzaki-
Huang (SHM) model describes the general mechanism utilized by most CAMPs in their 
microbial identification and lysis (Figure 4). In short, the model proposes: first, an 
electrostatic interaction between the peptides and membrane, followed by lipid 
displacement, leading to an alteration in the membranes structure which further promotes 
apoptosis [20].  
 
The exact mechanism by which CAMPs kill microbes is still undetermined, although, 
many hypotheses have been presented. Fatal depolarization (of the normally energized 
membrane), formation of physical holes (causing outward diffusion of cellular contents), 
and improper distribution of membrane components are among of the most prevalent 
ideas published in the literature [19]. 
 
Despite their unclear killing mechanism, CAMPs remain attractive antimicrobial agents. 
They have intrinsic bactericidal activity and appear to promote the efficiency of inhaled 
antibiotic aerosols. This enhancement is believed to be a product of the above stated 
Figur e 4:KEY: Phospholipid head groups: Yellow = (-) Charge / Black = No net charge 
a) Electrostatic interaction between bacterial outer leaflet and peptides. b) Thinning of the outer leaflet 
due to peptide integration. Outer leaflet grows disproportionally to inner leaflet causing strain (Jagged 
blue arrows) c) Pore formation d) lipids and peptides transported into the inner leaflet. e) Peptides bind 
intracellular targets leading to cell death (in some cases). f) Destruction of cellular membrane and cell 
death (other cases). Image taken from [6]. 
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disruption of the bacterial outer membrane, which facilitates the entry of additional 
molecules from the exterior, such as antibiotics [6, 21]. Once these molecules have 
reached the periplasmic space they then have a greater ability to integrate and transverse 
the cellular membrane to reach their intracellular cytoplasmic targets.  
 
Due to their intrinsic bactericidal efficiency, a large commercial effort has been set forth 
to create CAMP analogs which represent a class of clinical antimicrobials. Aerosolized 
Polymyxins, specifically, have re-emerged as useful clinical antibiotics and have been 
utilized to treat infections with P. aeruginosa as well as other multidrug-resistant Gram-
negative bacteria [22]. More specifically, Polymyxin E, otherwise known as colistin, is 
considered a last-resort treatment for chronic multidrug-resistant infections within current 
CF patients [22]. 
 
Crucial to the utilization of this field of clinical antimicrobials is an understanding 
of the bacterial modification pathway that confers resistance to CAMPs. An 
understanding of this pathway would allow for development of resistance inhibitors 
promoting improved bactericidal activity and extended clinical life for the 
antibiotic.  
 
CAMP Resistance Mechanism in P. aeruginosa 
 
Covalent modification of Lipid A is the 
main mechanism utilized by Gram-negative 
bacteria, including P. aeruginosa, to confer 
resistance to CAMPs and related 
antimicrobials. It has been demonstrated 
that bacteria make different forms of Lipid 
A in response to their environment [23]. 
The environment encountered by P. 
aeruginosa in the CF lung results in 
modification of its Lipid A with the 
positively charged sugar 4-amino-arabinose  
(Ara4NH4+)(Figure 5)[23, 24]. 
 
Covalent addition of Ara4NH4+ reduces the 
negative charge of outer bacterial 
membrane. Ara4NH4+ addition to Lipid A 
replaces a negatively charged phosphate 
with a positively charged primary amine. 
This modification confers resistance to 
CAMPs due to the decreased electrostatic 
interaction between the positively charged 
CAMPs and the negatively charged 
microbial outer leaflet. This unique Lipid 
A modification utilized by P. Aeruginosa within CF patients has been proven to 
establish a resistance against both CAMPs and Polymyxins [23, 25].  
Figur e 5: Molecular structure of Lipid A 
(Black) including some of the common 
bacterial modifications found in cells isolated 
from CF patients. the addition of L-Ara4N 
(blue), phosphoethanolamine (blue), and 
palmitoyl chain (red); the removal of 
hydroxymyrisotol chain (red); and the 
formation of 2-hydroxymyristate (red) [28]. 
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Figur e 6: (A) The currently proposed pathway for the biosynthesis of Ara4N and its addition to Lipid A (taken 
from[1]). First, UDP-glucose is oxidized to UDP-glucuronic acid by Ugd. Next, the ArnA C-terminal domain 
converts UDP-glucuronic acid to novel UDP-4-keto-glucuronic acid intermediate which is subsequently 
decarboxylated to UDP-4-ketopentose. UDP-4-ketopentose is then transaminated by ArnB using glutamate as 
the amine donor to yield the novel sugar-nucleotide UDP-4-aminoarabinose (UDP-b-L-Ara4N). UDP-b-L-
Ara4N is then formylated by the N-terminus of ArnA in order to drive the unfavorable reaction of ArnB 
forward. This transiently formylated product is used by ArnC to transfer Ara4N-formyl (AraFN) to 
undecaprenyl-phosphate with release of UDP. ArnD is proposed to deformylate undecaprenyl-phosphate-a-L-
Ara4FN, which is then flipped to the periplasmic side of the inner membrane by the heterodimeric ArnE/ArnF. 
Last, ArnT transfers Ara4N from the undecaprenyl intermediate to Lipid A to yield the final product [Ara4N]-
lipid A.  
 (B) Equivalence between the original Pmr and Current Arn nomenclatures.  
 
We hypothesize that inhibition of the biosynthetic pathway used to modify Lipid A with 
Ara4NH4+ in P. aeruginosa has utility in the treatment of CF patients. Inhibiting this 
pathway would effectively increase the susceptibility of the bacteria to host CAMPs and 
antibiotics that use a similar mechanism of action such as Polymyxins. 
 
Biosynthetic Pathway for Lipid A- Ara4NH4+ Addition: 
 
The enzymes responsible for mediating a resistance against CAMPs and Polymyxins via 
the biosynthetic addition of Ara4NH4+ to Lipid A are encoded by genes found at two 
different locations. Originally named Pmr (for Polymyxin Resistance), PmrE codes for 
UDP-glucose dehydrogenase, the first enzyme in the biosynthetic pathway. While, 
PmrHFIJKLM, at a different locus, is a seven-gene operon that encodes for the proteins 
that complete the biosynthetic pathway (Figure 6). This operon has been subsequently 
renamed ArnBCADTEF, (for Arabinose NH4+) following the order of reactions that 
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result in covalent addition of Ara4NH4+ to Lipid A [26-28]. Genetic deletion studies within 
the ArnBCADTEF operon have been used to demonstrate that all of the enzymes in the 
biosynthetic pathway are essential for the modification [29]. Since all the enzymes in the 
pathway are essential it allows for multiple biological targets to be targeted for inhibitor 
design. This in turn results in a higher probability for successful inhibition and thus 
abolition of the Lipid A modification pathway. 
 
The biosynthetic pathway, mediating the addition of Ara4NH4+ to Lipid A, begins with 
the oxidation of a primary alcohol on UDP-glucose to a carboxylic acid in UDP-
glucuronic acid. This reaction is catalyzed by the well-characterized dehydrogenase, Ugd 
(PmrE) [30]. Following this oxidation, the C-terminus of ArnA (PmrI) then catalyzes the 
oxidative decarboxylation of UDP-glucuronic acid to generate novel UDP-4-keto-
pyranose [31, 32]. This intermediate is then transaminated using Glutamate as the amine 
donor by ArnB (PmrH) in an unfavorable reaction to produce UDP-ß-L-Ara4N with an 
equilibrium constant of 0.1 [33]. It has been shown that the N-terminus of ArnA then 
catalyzes the addition of a formyl group from N10-formyl-tetrahydrofolate to produce 
UDP-Ara4N. It has been suggested, since there have been no formyl groups detected on 
Lipid A, that this reaction occurs in order to drive the previous unfavorable reaction 
forward [33, 34]. It is important to notice that the formylation of UDP-Ara4N has been 
well characterized, however, there has been no detection of a formylated product attached 
to Lipid A. Thus, the pathway calls for a deformylase activity within one of the 
uncharacterized enzymes. The formylated product, an L-Ara4N-formyl moiety, is then 
transferred to undecaprenyl phosphate by ArnC (PmrF) forming undecaprenyl phosphate-
αL-Ara4N-formyl. This crucial intermediate has been firmly established to accumulate 
within Polymyxin-resistant mutants of Escherichia coli and Salmonella typhimurium 
[35]. It has been hypothesized that this formylated intermediate is deformylated 
immediately by ArnD (PmrJ) followed by translocation of the Undecaprenyl Phosphate-
L-Ara4N by the heterodimeric ArnE/ArnF protein complex. Finishing the pathway, ArnT 
(PmrK) then transfers the sugar moiety to the Lipid A unit effectively synthesizing 
[Ara4NH4+]-Lipid-A. 
 
ArnD, A hypothetical undecaprenyl phosphate-α-L-Ara4N-formyl deformylase 
 
It has been determined through genetic mutation studies that the Protein ArnD is essential 
for [Ara4NH4+]-Lipid-A biosynthesis and thus CAMP resistance [29]. It has further been 
determined in our lab that ArnD is a membrane-associated enzyme (Lee, M. and Sousa 
M.S.; unpublished results). ArnD’s currently proposed function within the pathway is to 
catalyze the deformylation reaction of undecaprenyl-phosphate-Ara4(N-formyl) to 
generate the final Ara4NH4+ structure that is attached downstream to Lipid A (Figure 7). 
Inhibition of ArnD would facilitate disrupting the modification pathway and effectively 
abolishing this type of resistance of Gram-negative bacteria against CAMPs and CAMP-
like antibiotics such as Polymyxins. 
 
This project focuses on the biochemical and structural characterization of ArnD. A 
detailed understanding of ArnD structure and mechanism is required in order to 
design specific inhibitors, which target the unique catalytic properties of ArnD. 
ArnD is a superb target for inhibitor design for two reasons. First, because ArnD is 
essential to the biosynthetic addition of Ara4NH4+ to Lipid A; and secondly, and even 
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Figure 7: Sequence of reactions that lead to the synthesis of undecaprenyl-phosphate-Ara4N. 
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UDPOH
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UDPOH
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Phosphate-L-Ara4FN
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ArnA
UDP-L-Ara4-
Formyl-N
O
OH
OHHN
O
P
Undecaprenyl
Phosphate-L-Ara4N
O
OH
OHH3N
ArnDArnC
more enticingly, because no known eukaryotic enzymes catalyzes the same reaction, 
giving its potential inhibitor a high specificity. 
 
The complete genomic sequence of Pseudomonas aeruginosa was reported in Nature in 
2000 by the Pathogenesis Corporation. This was the largest bacterial genome sequenced 
at the time, with almost 6.3 million base pairs, and provided crucial insight to the intrinsic 
drug resistance of Pseudomonas aeruginosa [36]. Among this insight, was the 
sequencing of the ArnBCADTEF operon, which is responsible for the biosynthetic 
addition of Ara4NH4+ to Lipid A. This operon was found to be located between the 3.97 
and 3.98 million base pair region of the P. aeruginosa genome (Figure 8) and provided 
the evidence that this resistance pathway was present in P. aeruginosa.  
 
To increase the chances that the biochemical and structural characterization of these 
enzymes is successful, our lab has targeted the Arn enzymes from four model organisms: 
Escherichia coli, Salmonella typhimurium, Yersinia pseudotuberculosis and 
Pseudomonas aeruginosa. The amino acid sequence similarity amongst these orthologous 
proteins is ~80 %. This strongly suggests that the structural and biochemical 
Figure 8: A) ArnD gene location within the Pseudomonas aeruginosa genome. 
B) ArnD gene location within the ArnBCADTEF operon. Image from [36]. 
B) 
A) 
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characterization of ArnD from any one of these organisms will provide a similar, if not 
identical, model for all the others. 
 
Preliminary protein expression experiments within this lab showed that Salmonella ArnD 
could be expressed in E. coli with good yields. Therefore the experiments described in 
this work were carried out with the Salmonella ortholog. Salmonella and Pseudomonas 
ArnD share high sequence conservation (64% identity, 75% similarity) (Figure 9). We 
are therefore confident that the results obtained with Salmonella ArnD are applicable to 
all members of the family, including Pseudomonas. 
 
Figure 9: Key: * = Exact Match, : = Highly Conserved, . = Conserved, (Blank) = Not Conserved 
Polypeptide sequence alignment comparison of ArnD within Pseudomonas Aeruginosa and Salmonella 
Typhimuruim, Illustrates orthologous nature and sequence conservation of ArnD within varying forms 
of bacterial species 
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Project Rationale and Hypothesis 
 
A Blast search with ArnD showed weak but significant sequence similarity with members 
of the polysaccharide deacetylase superfamily (Figure 10). Polysaccharide deacetylases 
are metalloenymes, containing Zn2+ or Co2+ in their active site, that catalyze the 
hydrolysis of acetyl groups from polysaccharides. This suggests that ArnD may catalyze 
an analogous reaction: the hydrolysis of a formyl group from the sugar in undecaprenyl 
phosphate-αL-Ara4N-formyl 
 
Characteristic of the polysaccharide deacetylase family are three amino acid residues 
coordinating the metal ion, while His and Asp residues are directly involved in the 
catalysis. Figure 11 shows the sequence alignment of ArnD with six polysaccharide 
deacetylases of known structure. Although there is low overall sequence similarity, the 
residues important for metal coordination and catalysis appear conserved (Figure 11 
highlighted in blue and magenta, respectively). 
 
 
 
 
 
 
 
Figure 11: Sequence alignment of ArnD with polysaccharide deacetylases of known structure. 1W1A: 
carbohydrate esterase Bacillus subtilis; 1NY1: polysaccharide deacetylase Bacillus subtilis; 2J13: 
carbohydrate esterase Bacillus anthracis; 2IW0: chitin deacetylase Colletotrichum lindemuthianum; 
2C1G: peptidoglycan deacetylase Streptococcus pneumoniae; 2CC0: carbohydrate deacetylase 
Streptomyces lividans. Identical residues are shaded orange while conservative changes are shaded 
yellow. Residues involved in catalysis are highlighted in magenta while those involved in metal 
coordination are highlighted in blue. 
1W1A G P L G S V L L A G G A A Q A E A V P N E P I N W G F K R S V N H Q P P D A G K Q L N S L I E K Y D A F Y L G N T K E K T I Y L T F - - D N - G Y E N - - G Y T P K V L - D V L K K H - - R V T G - T F 91
1NY1 - - - - - - - - - - - - - - - - - V P N E P I N W G F K R S V N H Q P P D A G K Q L N S L I E K Y D A F Y L G N T K E K T I Y L T F - - D N - G Y E N - - G Y T P K V L - D V L K K H - - R V T G - T F 74
2J13 - - M G S - - - S H H H H H H M A Y T N T P H N W G I P R P K N E T V P D A G K L Y T D L L Q K N G G F Y L G D T K K K D I Y L T F - - D N - G Y E N - - G Y T G K I L - D V L K E K - - K V P A - T F 86
2IW0 - - - - - - - - - - - - M H F S T L F G A A A T A A L A G S T N A S - P L A R R Q V - - - - - P V G T P I L Q C T Q P G L V A L T Y - - D D - G P F - - - T F T P Q L L - D I L K Q N - - D V R A - T F 72
2C1G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - V A L T F - - D D - G P N P - - A T T P Q V L - E T L A K Y - - D I K A - T F 30
2CC0 - - - - - - - - - - - - - - - - - - - - - - - - A A - - - - - - - - - - - - - - - - - - - - - - - - - - - - - C N - - G Y V G L T F - - D D - G P S - - - G S T Q S L L - N A L R Q N - - G L R A - T M 35
ArnD - - - - - - - - - - - - - - - M T K V G L R I D V D T F R G T R E G V P - - - R L L - - - - - - - - E I L S K H N I Q A S I F F S V G P D N M G R H L W R L V K P Q F L W K M L R S N A A S L Y G W D I 74
1W1A F V T G H - - - - - F V - K D - Q P Q L I K R M S D E - G H I I G N H S F H H P D L T T K T A - - D - Q - I Q D E L D S - - - - V N E E V Y K - I T - - - - - G - K Q D N L Y L R P - - P R G V - F S E 165
1NY1 F V T G H - - - - - F V - K D - Q P Q L I K R X S D E - G H I I G N H S F H H P D L T T K T A - - D - Q - I Q D E L D S - - - - V N E E V Y K - I T - - - - - G - K Q D N L Y L R P - - P R G V - F S E 148
2J13 F V T G H - - - - - Y I - K T - Q K D L L L R M K D E - G H I I G N H S W S H P D F T A V N D - - E - K - L R E E L T S - - - - V T E E I K K - V T - - - - - G - Q K E V K Y V R P - - P R G V - F S E 160
2IW0 F V N G N N W A - - N I E A G S N P D T I R R M R A D - G H L V G S H T Y A H P D L N T L S S - - A - D - R I S Q M R Q - - - - L E E A T R R - I D - - - - - G - F A P - K Y M R A - - P Y L S - C D A 150
2C1G F V L G K - - - - - N V - S G - N E D L V K R I K S E - G H V V G N H S W S H P I L S Q L S L - - D - E - A K K Q I T D - - - - T E D V L T K - V L - - - - - G - S S S - K L M R P - - P Y G A - I T D 103
2CC0 F N Q G Q - - - - - Y A - A Q - N P S L V - R A Q V D A G M W V A N H S Y T H P H M T Q L G Q - - A - Q - M D S E I S R - - - - T Q Q A I A G - A G - - - - - G - G T P - K L F R P - - P Y G E - T N A 108
ArnD L L A G T A W P G K E I G H A - N A D I I - R E A A K - H H E V G L H A W D H H A W Q A R S G N W D R Q T M I D D I A R G L R T L E E I I G Q P V T C S A A A G W R A D Q K V I E A K E A F H L R Y N S 171
1W1A Y V L K E T - - K R L - - - G - Y Q T V F W S - - V A F V D W K I N N Q K G K K Y A - - - Y D H - M I K - Q A - - H P G A - I Y L L H - T V S R - D N A E A L D - D A I T D L K K Q G Y T F K S I D D L 246
1NY1 Y V L K E T - - K R L - - - G - Y Q T V F W S - - V A F V D W K I N N Q K G K K Y A - - - Y D H - X I K - Q A - - H P G A - I Y L L H - T V S R - D N A E A L D - D A I T D L K K Q G Y T F K S I D D L 229
2J13 R T L A L T - - K E M - - - G - Y Y N V F W S - - L A F L D W K V D E Q R G W Q Y A - - - H N N - V M T - M I - - H P G S - I L L L H - A I S K - D N A E A L A - K I I D D L R E K G Y H F K S L D D L 241
2IW0 G C Q G - - - - - D L - - - G G L G Y H I I D T N L D T K D Y E N N K P E T T H L S A E K F N N - E L S A D V G - A N S Y - I V L S H - D V H E - Q T V V S L T Q K L I D T L K S K G Y R A V T V G E C 237
2C1G D I R N - - - - - S L - - - D - L S F I M W D - - V D S L D W K S - K N E A S I L T - - - - - - - E I Q H Q V - - A N G S - I V L M H - D I H S - P T V N A L P - R V I E Y L K N Q G Y T F V T I P E M 178
2CC0 T L R S V E - - A K Y - - - G - L T E V I W D - - V D S Q D W N N - A S T D A I V Q - - - - - - - A V S - R L - - G N G Q - V I L M H - D W P A - N T L A A I P - R I A Q T L A G K G - - L C S - G - M 181
ArnD D C R G A M P F R P L L E S G N P G T A Q I P - - V T L P T W D E V I G R D V K A E D - - F N G W L L N - R I L R D K G T P V Y T I H A E V E G C A Y Q H N F V - D L L K R A A Q E G V T F C P L S E L 265
1W1A M F - - E - - - K E - - M R L P S L - - - - - - - - - - - - - 2 5 7
1NY1 X F - - E - - - K E - - X R L P S L - - - - - - - - - - - - - 2 4 0
2J13 V - - - - - - - K S - - N Q - P - - - - - - - - - - - - - - - 2 4 7
2IW0 L G D A P - - - E N W - Y K A H H H H H - - - - H - - - - - - 2 5 4
2C1G L N T R L - - - K A - - H E L Y Y S R D - - - - E - - - - - - 1 9 4
2CC0 I S - - P - - - Q T - - G R A V A P D G - - - - S - - - - - - 1 9 5
ArnD L S E T L P L G Q V V R G N I A G R E G W L G C Q Q I A G S R 2 9 6
Figure 10: Blast search of ArnD sequence confirming relation to Polysaccharide Deacetylase Superfamily. 
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The conservation of residues important for catalysis suggests that ArnD may utilize a 
hydrolysis mechanism similar to that of polysaccharide deacetylases. The catalytic 
mechanism of these metal dependent hydrolases is shown in Figure 12, using the Zn2+ 
dependent peptidoglycan deacetylase as an example [37-39].  
In this mechanism a His and an Asp act as a general acid and base, respectively, to help 
hydrolyze the substrate. For this reaction a zinc-bound H2O molecule is the nucleophile 
[39]. First, the zinc ion polarizes the side chain carbonyl oxygen on Asp. The aspartate 
residue then acts as a general base catalyst, activating the water molecule. This 
hydroxyde ion attacks the electrophilic carbonyl carbon of the substrate. The histidine in 
the catalytic pair then donates it’s proton to the negatively charged intermediate, 
completing the hydrolysis. Within this catalytic model zinc acts to stabilize the 
tetrahedral oxyanion intermediate [39]. Within this example, zinc is used as the ionic 
species. However, it has been demonstrated that the coordinating metal ion is enzyme 
specific with Zn2+[37, 39] and Co2+[40] being the most frequent.  
 
Given the necessity of a deformylase in the Lipid A-Ara4(NH4+) biosynthesis 
pathway and the conservation in ArnD of residues important for deacylation in 
related enzymes; it is my hypothesis that ArnD catalyzes the deformylation of 
undecaprenyl-phosphate-Ara4(N-formyl) utilizing a similar catalytic strategy as 
used by polysaccharide deacetylases. 
 
 
 
 
 
 
 
 
 
 
Figure 12: An example of the proposed catalytic mechanism for polysaccharide deacetylases and 
congruently for ArnD 
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Specific Goal: 
 
I will test my hypothesis with point mutations of the putative catalytic residues: Asp43 and 
H233; followed by an evaluation of the mutation’s effect on ArnD activity. The catalytic 
residues were chosen first for mutation over the metal coordinating residues because only 
a single point mutation is likely necessary to affect activity. Mutating the metal 
coordinating residues may require mutation of two residues to confer a change in activity. 
Furthermore, a single point mutation is less likely to disturb the native fold of the 
enzyme. Ideally, the mutation would have no effect on the native fold, yet would not 
produce product do to the intrinsic loss of hydrolase activity. This circumstance would 
lend itself greatly towards crystallization and structure determination, which would 
further aid in specific inhibitor design. 
 
Choice of mutations: 
 
The catalytic residues, Asp43 and His233, must be mutated into the most conservative 
mutations in order to maintain the native fold of the protein. For a protein folding in 
solution: the fold is primarily due to the hydrophobic effect, which is an entropically 
driven process.  
 
The mutations that are most conservative were determined by Jonson et. al. and can be 
viewed in Figure 13 [2]. This figure describes the correlation between each individual 
amino acid residue and their distribution within known protein structures. Green regions 
represent a positive correlation, 
indicating residues that inhabit a similar 
protein environment, while red areas 
indicate negative correlation and white 
regions demonstrate a low degree of 
correlation either positive or negative. 
As can be seen in the figure, aspartate, 
D, shows a high degree of correlation 
with only two residues: serine and 
asparagine or S and N, respectively. On 
the other hand, histidine shows very little 
positive or negative correlations with any 
amino acid residues. However, some 
positive correlation can be seen in 
tyrosine, tryptophan and arginine, (Y, W 
and R, respectively). Therefore, 5 
specific point mutations will be made to 
WT ArnD: aspartate 43 to asparagine 
and serine (D43N and D43S), and 
histidine 233 to tyrosine, tryptophan and 
arganine (H233W, H233Y, and H233R). 
Due to the conservative nature of these 
mutations, we expect them to not disrupt 
the structure of the enzyme. 
 
Figure 13: Demonstrates various correlations 
between different amino acids and their relative 
distribution within known enzymes. Green Areas 
represent a positive correlation. Red Areas 
represent a negative correlation. White areas have a 
low degree of correlation. Figure take from [2, 3].  
 17 
Following mutagenesis of an expression plasmid, ArnD and its mutants will be extracted 
from membranes and purified optimizing the yield of non-aggregated protein. The 
enzymes will then be assayed for their ability to catalyze the deformylation of 
undecaprenyl-phosphate-Ara4(N-formyl) to yield undecaprenyl-phosphate-Ara4N. The 
substrate for ArnD is not commercially available and will be produced by sequential 
enzymatic transformations of UDP-Glucuronic acid. TLC separations will be used to 
monitor product formation for each enzymatic step as well as evaluation of ArnD 
activity.  
 
My project tests whether ArnD does indeed catalyze the deformylation reaction of 
undecaprenyl-phosphate-Ara4(N-formyl) to yield undecaprenyl-phosphate-Ara4N. 
Further my experiments test whether the mechanism of this deformylation is similar 
to the mechanism utilized by the polysaccharide deacetylase family. The expectation 
is that these experiments will validate the role of ArnD in Lipid A-Ara4NH4+ 
biosynthesis and provide valuable information for development and evaluation of 
inhibitors. These may prove valuable leads for development of clinical inhibitors to 
treat Pseudomonas infections in CF patients and extend the clinical life of antibiotics 
such as colistin. 
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Results 
 
Mutated Plasmid Design and Amplification 
 
 
The plasmid used for gene introduction, cloning, and expression was a modified parent 
vector pET28a(+) containing a Kanamycin resistance cassette (Figure 14). This vector 
was modified in our lab to introduce additional restrictions sites and tags for purification 
resulting in plasmid pMS174. The gene coding for Salmonella ArnD had been previously 
cloned into this vector (M.S. Lee unpublished data) resulting in the full-length protein 
with a 6 X Histidine tag at its C-terminus (Figure 15).  
 
As described in detail in materials and methods, the Quikchange method (Stratagene) was 
used to introduce point mutations in the ArnD expression plasmid. Oligonucleotide 
primers were designed to specifically target the codons within the ArnD gene, 
responsible for the addition of Asp43 and H233 into the polypeptide chain. Upper and 
lower primers were synthesized for each mutation: D43N, D43S, H233W, H233Y, 
H233R. These primers were ~40 bases in length, with a minimum GC content of 40%, 
and ~15 bases on either side of the desired mutation codon. These parameters ensure 
proper annealing to the parent vector during subsequent PCR thermocycling and 
amplification. Following PCR amplification of the plasmid, digestion with Dpn1 
endonuclease served to degrade the parent (wild type) vector so that only the new, 
mutated plasmid remained. Figure 16 shows the analysis of the mutagenized PCR 
products performed on 0.8% agarose gel electrophoresis, depicting clean amplified 
Figure 15: pMS174 vector map. Important 
features are: ArnD gene, 6x His TAG at 3’ 
end of ArnD, and Kanamycin Resistant 
cassette. 
Figure 14: pET-28a(+) vector map. Important 
features are: MCS region, TEV-site, lac1, 6x His TAG 
at 5’ end of MCS, and Kanamycin Resistant cassette. 
Figure taken from [3]. 
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products. The intensity and location of the bands confirms successful generation of the 
desired mutant plasmids.  
 
The original vector was ~6Kb and the addition of the ArnD gene was roughly ~1.1 Kb in 
length. The mutated plasmids were used to transform XL-10 competent E. coli cells 
which were plated on LB medium supplemented with Kanamycin. Individual colonies 
were used to prepare plasmid DNA. Then, individual clones were selected and submitted 
for sequencing using the T7 promoter and terminator primers, confirming the presence of 
desired mutations in all five mutants.  
 
 
 
 
 
 
 
 
 
 
 
Figure 16: 0.8% agarose gel in 0.5% TAE Buffer stained by EtBr depicting PCR amplification of 
pMS174 vector containing ArnD gene using cycling parameters used under Stratagene protocol (see 
material and methods). The insert band was detected just above 7 kb on 0.8% agarose gel, which suggests 
proper insertion and amplification of the mutated ArnD gene vector ~7.1 kb in size. Negative control 
reaction represents an identical reaction run under the same conditions without the addition of Pfu turbo 
polymerase. 5 µL of sample was added to each well, ran at 135 V for ~30 min. 
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Protein Expression and Purification 
 
Protein expression was carried out using E. coli Bl-21 competent cells as a host. Prior to 
large-scale protein preparations, small-scale expression tests were conducted to evaluate 
expression of the desired protein, ArnD. Several colonies were selected for each 
individual mutation and compared using SDS PAGE before and after expression 
induction (Figure 17).  
 
 
The basic protocol for protein purification includes: (1) cell lysis, (2) protein extraction 
from the membrane, (3) affinity purification using Ni-NTA agarose and (4) size 
exclusion chromatography (SEC) to evaluate the presence of aggregates in the purified 
sample. 
 
 
 
 
 
 
Figure 17: SDS-PAGE gel depicting expression optimization conditions of ArnD. Before Gel: Lane 1 is 
a standard protein marker, Lanes 2 through 11 contain before induction (-IPTG) samples of 2 separate 
colonies of the 5 different mutations. After Gel: Lanes 1- 10 depict the same 2 separate colonies of the 5 
different mutation used in the before gel after induction (+IPTG) overnight at 20°C. All mutant 
constructs express a high level of protein at the desired location, however, only the colonies which 
expressed best were carried forward for large-scale expression and purification. 
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Figure 18: Y-Axis: Absorption at 280 nm;  X-Axis: mL eluted/fraction # 
Elution of WT ArnD expressed in two separate conditions after Ni-NTA Affinity Chromatography & HiLoad 
26/60 Superdex 200 Size Exclusion Chromatography. In Both Graphs: there is an initial peak ~ Fraction 28 
representing aggregate protein followed by a second peak of the desired detergent soluablized membrane protein 
at ~Fraction 44. At RT, there is an increase in absorbance of the second, solubalized ArnD, peak both relative to 
the first peak and in general. At RT, Aggregate: Soluabalized 1100 mAU: 1350 mAU; at 16° C, Aggregate: 
Soluabalized 800 mAU: 400 mAU. 
 
Small-scale purification allowed for the refinement of expression conditions. Expression 
induction was carried out at various temperatures to maximize the yield of unaggregated 
protein as judged by SEC. The best two experimental conditions are shown in Figure 18. 
The results demonstrate the smallest proportion of aggregated protein (First peak around 
Fraction 28) as compared to unaggregated protein (second peak around Fraction 44) 
when the expression is carried out at 20 C, or approximately room temperature. 
 
 
Additional small-scale purification tests were performed to define the best detergent for 
membrane extraction (Figure 19). The effect of detergent in the protein yield was 
evaluated by SEC (using a Superdex 200 column) and SDS PAGE analysis of the 
fractions. As shown in Figure 19, Triton-X-100 solubilizes the membrane protein ArnD 
better than the detergents: n-Dodecyl β-D-maltoside (DDM), N,N-
Dimethyldodecylamine N-oxide (DDAO), Deoxycholate, 3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propanesulfonate (CHAPS) , and n-Octyl-β-D-Glucopyranoside 
(OG) at the concentrations used. This conclusion was made based on the thick band 
indicating high protein concentration both after membrane solubilization, Ni-NTA elution 
and similarly after SEC. Furthermore, this high concentration of protein is also confirmed 
by spectral analysis of the eluted SEC column at 280 nm.  
 
 
 
 
 
 22 
Following the refinement of expression and purification of experimental parameters, each 
mutant, as well as WT ArnD, was expressed and purified under identical conditions. 
Approximately 6 L of E. Coli  cells transformed with the appropriate plasmid were 
grown, induced and harvested. Wild-type and mutant ArnD were purified using Ni-NTA 
affinity chromatography. This method of purification is highly selective for the desired 
protein, ArnD, due to the high affinity of binding of the resin to the attached C-terminus 6 
x His TAG on the ArnD constructs. Elution of ArnD, and ArnD mutants, is achieved by 
competitive binding of imidazole to the Ni-NTA resin. Along the expression and 
purification sequence, various aliquots were taken for SDS PAGE analysis to confirm 
proper expression and purification. Figure 20 shows a representative SDS-PAGE 
evaluating the large-scale purification of ArnD H233R. These purification procedures 
and corresponding gels were reproducible and essentially identical between each 
construct. 
Figure 19: For each graph for each individual detergent: Y-Axis: Absorption at 280 nm;  X-Axis: mL 
eluted/fraction number 
Elution of WT ArnD solubilized in six separate detergents after Ni-NTA Affinity Chromatography & HiLoad 
26/60 Superdex 200 Size Exclusion Chromatography. Triton X-100 (top middle) was found to be the best 
detergent for the solubilization of the membrane associated enzyme ArnD. This can be seen in the various graphs 
where Triton X-100 has the most defined single absorbance peak at ~ Fraction 10 ~1400 mAU. This is further 
supported by SDS PAGE analysis. By loading the same volume it can be seen, by the thick band in lane E, that 
there is the highest protein concentration in Triton- X-100 detergent as opposed to the others tested. This is also 
further exemplified by the lanes 7-13, indicating a single peak of protein at ~33KDa, the size of WT ArnD. 
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As can be seen in Figure 20, there is a protein band located slightly above the 30 KDa 
marker. This band corresponds with the ~33KDa enzyme ArnD. After induction with 
ITPG and expression overnight there is a dramatic increase in the concentration of ArnD 
present. Cell lysis was performed with a French Press. Sonication should be avoided 
because membrane proteins tend to aggregate upon sonication. A low speed 
centrifugation step removed cell debris and a large amount of ArnD. This removal is 
most likely due to misfolding and association into inclusion bodies. The remaining 
fraction undergoes two centrifugation steps resulting in a membrane pellet. This pellet is 
solubilized using the detergent Triton X-100, ran through a Ni-NTA, and eluted with 
imidazole (lane E Figure 20). This column represents the elution of ArnD, at ~33KDa in 
the presence of very little contaminant protein. This sample was concentrated and 
subjected to Size Exclusion Chromatography.   
 
Figure 20: Similar gels were produced for WT ArnD as well as all 5 mutants: 
12% SDS-PAGE gel depicting expression and purification of H233R mutant ArnD. (A detailed 
explanation of the various lanes can be found within materials and methods) Lane 1 is a standard protein 
marker, (B) is before induction (-IPTG). (A) is after induction (+IPTG), (L) is lysate, (T) is total soluble 
and membrane protein, (S) is soluble protein, (M1) is total membrane protein, (M2) is actual membrane 
protein, (F) is Flow-Through Ni-NTA, (W1) is wash with 0.1% Triton X-100, (W2) is wash with x5 
CMC DDM, (E) is eluted protein from Ni-NTA. overnight at 20°C. All mutants as well as WT ArnD 
expressed a large amount of protein, followed by successful purification. This can be seen by looking at 
the Elution lane (E). There is a significant amount of desired protein just above the 30 KDa marker. This 
is representative of the ~33KDa H233R mutant ArnD construct. 
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Figure 21 depicts the final SEC step for the large-scale purification of ArnD. The SDS 
PAGE analysis of the fractions show that ArnD is highly purified. As before, these gels 
were highly reproducible and relatively identical between each construct; all mutant and 
WT constructs demonstrated similar protein yield, purity and location during elution. The 
purified proteins were frozen at -70 C for later activity analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Similar gels and elutions were produced for WT ArnD as well as the 5 mutants: 
Left:12% SDS-PAGE gel depicting purification of WT ArnD. (A detailed explanation of the various lanes 
can be found within materials and methods) There are 9 Fractions: 41-49 all containing some concentration 
of desired protein just above the 30 KDa marker. This is representative of the ~33KDa WT ArnD construct. 
The top of the peak, where there was maximum absorbance at 280 nm, was at the end of Fraction 44 This 
can be visualized by the thick bands in lanes 44 and 45. 
Right: UV-Vis Spectral analysis at 280 nm of S200 SEC representative of all constructs both WT and 
Mutant. As can be seen by the figure there is a minimal first peak located around Fraction 28 which 
represents aggregated protein and other contaminants. The next sharp high absorption monomeric peak  
demonstrates a high concentration of purified ArnD mutant protein for activity analysis. 
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ArnD Substrate Formation 
 
Due to the lack of a commercially available substrate for ArnD, I had to produce it. To 
this end, I took advantage of radioactively labeled UDP-glucuronic acid and purified 
enzymes of the Arn pathway to enzymatically produce undecaprenyl phosphate-α-L-
Ara4N-formyl. The progress of the reaction was evaluated using Thin Layer 
Chromatography (TLC) and exposure to a PhosphoImager screen (Figure 22).  
 
 
It can be seen by comparing the first and second lanes in Figure 22 that there is complete 
conversion to product catalyzed by the C-terminal (dehydrogenase) domain of ArnA in 
the presence of exogenous NAD+. The product, UDP-4-keto-pyranose, is the substrate for 
ArnB. The transamination reaction catalyzed by ArnB in the presence of glutamate as the 
amine-donor, has an equilibrium constant of approximately 0.1 [33]. Thus, in order to 
generate a complete conversion of reactant to product a relatively high concentration of 
Glu was used to drive the reaction forward. The ArnB product, UDP-ß-L-Ara4N, can be 
visualized in the third lane with the farthest migration. This molecule has a protonated 
primary amine which holds a positive charge within the solvent system used and does not 
interact strongly with the PEI stationary phase. The last naturally soluble product in the 
Arn pathway is UDP-L-Ara4N-formyl, represented by the final lane of the TLC plate. 
Figure 22: Left: The Arn Reaction pathway, in order to give reference to the TLC plate 
Right: PEI Cellulose TLC plate ran in .4 M LiCl and .25 M Acetic Acid. The lanes contain: the initial 
substrate (UDP-[14C]glucuronic acid, first from the left) and the products after sequential incubation of 
the initial substrate with ArnA-CTD (dehydrogenase), ArnB, and ArnA-NTD (transformylase) (second, 
third and fourth lane, respectively). The figure illustrates the relatively complete conversion of substrate 
to product in each step.  
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Similar to the previous lanes, there appears to be a complete conversion of reactant to the 
formylated product after the addition of full length ArnA to the reaction mixture along 
with exogenous N-10-methenyltetrahydrofolate. The Rf values for UDP-Glucuronic 
Acid, UDP- 4-keto-pyranose, UDP-ß-L-Ara4N, and UDP-L-Ara4N-formyl are 0.09, 
0.45, 0.85 and .54 respectively. These results were obtained several times by myself and 
are consistent with the Rf values available in the literature where the identity of the 
products was verified by NMR and mass spectrometry [31, 33, 41]. 
 
The next step in obtaining the substrate for ArnD was the transfer of the N-formylated 
sugar to the undecaprenyl phosphate carrier. This was accomplished by mixing the 
previous reaction products with undecaprenyl phosphate solubilized in Triton X-100 and 
purified ArnC [41]. The conversion to the lipid-anchored sugar was monitored by TLC in 
Silica plates followed by PhosphoImager analysis (Figure 23). As before, the conversion 
to Undecaprenyl-Phosphate-L-Ara-4N-formyl appears fairly complete, and the Rf= 0.37 
of the product is consistent with the literature [41].  
 
 
Figure 23: Left: The Arn Reaction pathway, in order to give reference to the TLC plate 
Right: TLC Silica gel 60 F254 plate ran in (64/25/3.6/0.4) (CHCl3/MeOH/H20/NH4OH). The two lanes 
represent the migration of product along the Arn pathway. Starting with ArnA-NTD Product, UDP-L-
Arn4N-formyl, first from left and the product after incubation with ArnC and Undecaprenyl Phosphate 
resuspended in Triton X-100. The figure illustrates the relatively complete conversion of substrate to 
product.  
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Evaluation of ArnD activity 
 
With radiolabeled Undecaprenyl-Phosphate-L-Ara-4N-formyl in hand, I was now in a 
position to test if ArnD can convert this substrate to the deformylated product. In 
complementary experiments in our lab, Dr. MyeongSeon Lee was able to crystallize 
ArnD for structure determination by X-ray crystallography. During his initial 
characterization of the crystals, he observed X-ray absorption and fluorescence 
characteristic of Co2+ (Lee M.S. and Sousa M.C. unpublished results). These results are 
consistent with the hypothesis that ArnD is a metal dependent hydrolase and strongly 
suggests that the native metal was indeed Co2+. Therefore, I assayed the activity of ArnD 
supplementing the reaction mixture with 0.5 mM CoCl2 and different concentrations of 
purified, WT ArnD (Figure 24). 
 
As shown in Figure 24, there is clear formation of a species with migration slower from 
that of the initial substrate (time t=0). The substrate is fully converted to this slower-
migrating species in 48 minutes in the presence of 0.05 mg/ml ArnD. The amount of 
slower-migrating species formed decreases drastically as the concentration of WT ArnD 
is reduced. This suggests that the slower-migrating product is due to a reaction catalyzed 
by ArnD. This reaction is proposed to be the deformylation of Undecprenyl-Phosphate-L-
Ara4N-formyl to Undecaprenyl-Phosphate-L-Ara4N. 
 
I utilized a similar reaction mixture and strategy to evaluate the activity of the five ArnD 
mutants. As seen in Figure 25, the reaction for WT ArnD was reproducible and yielded 
essentially complete conversion into product within 48 minutes. Conversely, all five 
mutants showed dramatic reduction of activity. However, D43N appears to have some 
residual activity as a small amount of product can be seen in the later time points (Figure 
25, panel D43N). 
 
 
 
Figure 24: TLC Analysis of varying amounts of ArnD incubated with 0.5 mM CoCl2 and approximately 
0.8µM Undecaprenylphosphate-L-[14C]Ara4N-formyl (in a mixture containing all the preceding Arn 
pathway enzymes and reactants).  
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These results are consistent with my hypothesis that ArnD is an enzyme which 
catalyzes a reaction with the substrate undecaprenyl-phosphate-Ara4(N-formyl) to a 
slower-migrating species, we expect this reaction to be a deformylation producing 
undecaprenyl-phosphate-Ara4N. These results are also consistent with the notion 
that ArnD uses a catalytic strategy similar to that of polysaccharide deacetylases. 
This is supported by the presence of Co2+ in natively folded ArnD as well as the 
explicit loss of activity in all mutants of the putative catalytic duo aspartate 44 and 
histidine 233 characteristic of these enzymes.  
Figure 26: Identical assay as preformed in Figure 25, with duplicate results of WT ArnD and results of 
the 5 mutant ArnD constructs:  
TLC Analysis of ArnD activity, 0.05 mg/mL  WT ArnD and 5 mutants incubated individually with 0.5 
mM CoCl2 and approximately 0.8µM Undecaprenylphosphate-L-[14C]Ara4N-formyl (in a mixture 
containing all the preceding Arn pathway enzymes and reactants). 
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Discussion 
 
In the experiments described above there was successful introduction of point mutations 
in the ArnD expression plasmid. The intensity and location of the vector bands after PCR 
amplification confirmed successful generation of the desired mutant plasmids and was 
further confirmed by sequencing.  One of the potential problems of making point 
mutations is improper annealing to the WT gene. Since there is not proper Watson-Crick 
base pairing at the point mutation site it is possible that the oligonucleotide primer will 
not bind. In addition, it is also possible that during PCR amplification random undesired 
mutations are introduced along with the desired ones. This fact was taken in to 
consideration and thus two separate reactions for each mutation were submitted for 
sequencing. Sequencing results confirmed the absence of undesired mutations, and the 
presence of the designed ones. 
 
Intrinsic with the introduction of point mutations to WT proteins is the possibility of 
misfolding. The exact structural and electrostatic properties of each individual residue are 
unique and thus changing even a single residue has the potential to disrupt the native fold 
of the enzyme. However, this has not prevented the use of point mutation studies in 
regard to determining putative catalytic residues. Mutagenic analysis has led to the 
determination of catalytic residues for many enzymes both within our lab as well as labs 
across the globe. One way that point mutations are typically introduced is via the 
replacement of any given residue with alanine. By replacing the side chain on any given 
amino acid with a simple methyl group, as long as the side chain is active in catalysis, 
this typically inhibits the enzyme activity. Despite this, in regard to the two residues 
mutated within this experiment, aspartate and histidine, there is very little structural or 
electrostatic similarity to alanine. Due to these varying features, it is unlikely that His or 
Asp would inhabit a similar enzymatic environment as Ala would. Thus, in both cases, 
aspartate and histidine, were not mutated to Ala because of the potential to disrupt the 
enzyme folding. Instead, the mutations were designed to minimize the disturbance of the 
proteins native fold. In theory, these mutations have a greater probability mimicking a 
relatively similar environment of the active site both spatially and electrostatically from 
mutant ArnD as compared to WT ArnD. Such an environment would further promote 
proper substrate/enzyme binding and allow a better evaluation of the specific role of the 
side chains in catalysis.  
 
By using a series of mutations for a single residue, one increases the likelihood of 
obtaining a loss of activity not due to protein misfolding, but rather due to the loss of a 
crucial catalytic residue. The mutation D43S is a mutation determined by Jonson et. Al to 
have a 0.9-1.0 degree of correlation (Figure 13), the highest range possible. This would 
then suggest that a mutation from Asp to Ser would have minimal disturbance as 
compared to a mutation of Asp to another residue. Despite this, it seems possible that the 
different structural properties of the side chains of aspartate and serine could perturb the 
putative active site. Therefore, I also mutated D43 to asparagine, which is nearly identical 
to aspartate, with only the relatively mild alteration of a single functional group from 
carboxylic acid to an amide. Thus, a D43N point mutation is one of the most conservative 
mutations possible.  
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Nevertheless, protein misfolding is always a possibility when point mutations are being 
introduced. The only way one can confirm that the native fold of the enzyme is conserved 
and not perturbed by the mutations is through crystallization studies followed by structure 
determination. Despite the fact that we cannot say positively at this moment in time that 
the mutants folded correctly, there are distinctive clues which lead us to this notion. First, 
after lysing, the cellular lysate was centrifuged in order to remove any of the unlysed 
cells, various cellular debris, and inclusion bodies containing a majority of the misfolded 
enzymes within the cell. It can be seen in Figure 20 that total protein concentration, from 
the cellular lysate to the after centrifuged product, is decreased dramatically due to the 
removal of all misfolded enzymes during the expression period. Second, the S200 size 
exclusion analysis also suggests a properly folded enzyme. Unfolded proteins that are 
were not removed in inclusions bodies remain as aggregated proteins. A misfolded 
enzyme often has the potential of exposing normally hidden hydrophobic residues, which 
results in aggregation and elution early in size exclusion chromatography. This 
aggregation can be visualized in Figure 21 in the UV trace of the S200 elution. The first, 
smaller absorption peak, is representative of the earlier, larger, aggregated elution at 
Fraction 28. The second higher absorption peak is representative of the solubilized 
membrane protein ArnD in WT and all 5 mutant forms. Finally when looking at the 
purified WT ArnD alongside purified mutant ArnD the solutions look identical. There is 
no cloudiness in the either solution, which is a common visual indicator of protein 
aggregation.  
 
Assuming that there was a not intrinsic loss of enzymatic activity due to the misfolding of 
the 5 mutants, it must still then be determined how the mutants produce a loss of activity. 
It was stated that the specific point mutations made were the most conservative available. 
Is it possible then that these replaced residues can also support the same function in 
catalysis?  
 
The D43N mutation replaces the active base in catalysis with a side chain pKa ~4 to an 
amide. The amide group replacing the carboxylic acid is a very weak base, however, it is 
possible, that Asn positions the water molecule correctly in the active site and still 
supports, with much lower efficiency, the hydrolysis of the formate group of 
Undecaprenyl Phosphate-L-Ara-4N-formyl. This could explain the residual activity 
observed for D43N in Figure 25. 
 
For D43S the loss of catalysis seems more obvious, it is unlikely that the serine side 
chain will act as a general base deprotonating the water molecule to become a positively 
charged species. Although, in some circumstances the pKa of the side chain alcohol can 
be reduced within the enzyme allowing it’s alkoxide form to act as a base, it can be seen 
in Figure 25 that the D43S mutation does not support conversion of the ArnD substrate to 
product. Similarly, mutation of H233 to W, Y or R confers a dramatic loss of activity. 
The histidine which has a pKa ~7 depending on the relative environment is an ideal 
molecule for proton donation to the developing product. W, Y, R side chain available 
protons have the relative pKas of approximately 21, 17 and 12, respectively. Therefore, 
these residues would not be good general acids, consistent with the lack of activity seen 
in the H233 mutations.  
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The TLC analysis by PhosphoImaging demonstrated a clear, full, conversion of ArnC 
product and ArnD substrate to a new product; confirmation of the identity of this product 
will require MS and NMR. However, we believe that ArnD did indeed deformylate 
Undecaprenyl Phosphate Ara4N-formyl. The direct increase in product formation with all 
other variables held constant suggests that ArnD is indeed catalyzing a reaction and it is 
not some contaminant. In addition, on a Silica gel plate, polar molecules bind to the 
stationary phase while less charged molecule migrate further up the solvent front. This 
trend is consistent in our proposed identity of the migrating species.  
 
Due to the novel nature of these results from any published data, a number of future 
studies can be devised. Crucial to confirming the above stated results is a scale-up of the 
reactions with non-radioactively labeled substrates, purification by HPLC and submission 
to Mass Spectrometry and NMR analysis. Furthermore these mutants should be 
crystallized under the same conditions which WT ArnD had been successfully 
crystallized for structure determination by X-Ray diffraction. These studies will serve to 
undoubtedly confirm the identity of ArnD as a deformylase with His233 and Asp43 active 
in catalysis.  
 
My results are consistent with the reaction mechanism proposed for polysaccharide 
deacytlases shown in Figure 13. Therefore, analogs mimicking the tetrahedral 
transition-state may prove to be good inhibitors of the reaction mechanism.  
 
In order to give insight into potential specific inhibitor design, the class of zinc proteases 
can be utilized. These enzymes, similarly to ArnD, are metalloenzymes which catalyze a 
hydrolysis reaction. For this reason, specific inhibitors, designed for zinc proteases, 
which target the divalent metal as a crucial member of catalysis, could be extrapolated to 
be useful within ArnD. In addition to this, transition-state analogs could be created that 
mimic the tetrahedral intermediate undergone in the reaction mechanism after 
nucleophilic attack of the activated water molecule on the carbonyl carbon of the 
deformylated product.  
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Materials & Methods 
 
Site-Directed Mutagenesis: Using the JSH-C vector generously received from MyeongSeon Lee, five 
individual point mutations were introduced at two separate locations. These point mutations were made 
using mutagenic oligonucleotide primers amplified by PCR according to the Quickchange method 
(Stratagene protocol). First, the two primers, upper and lower, for each point mutation were designed and 
ordered from (Integrated DNA Technologies [IDT], Inc.) (Table 1). Next, the ordered HPLC-purified 
oligonucleotide primers were used to set up mutagenic PCRs containing: 
5 µL of 10X Pfu Buffer, ~20 ng of JSH-C DNA vector, 125 ng of oligonucleotide primer (both upper and 
lower), 1 µL 10 µM dNTP, and ~40 µL of ddH2O to obtain a final volume of 49 µL. Lastly, 1 µL of Pfu 
turbo polymerase (Stratagene)was added followed by subsequent PCR thermocycling. Thermocycling 
parameters used were: 
 (1) 95ºC for 3 minutes, (2) 95ºC for 1 minute, (3) 55ºC for 1 minute, (4) 72ºC for 13 minutes (2 min/kb 
plasmid), repeat steps 2-4 16X, (5) 72ºC for 10 minutes, (6) 4ºC until sample is used for analysis and 
further experimentation. Further, the template plasmid DNA was digested by adding 1 µL Dpn I restriction 
endonuclease (New England BioLabs, Inc.) and incubating for 1 h at 37°C to hydrolyze then adding 1 
additional µL Dpn I and incubating overnight. DNA Agarose Gels: In order to measure for sufficient and 
appropriate amplification of our mutated vector: 10µl of all the crude PCR products were run in Tris-
Acetate-EDTA (TAE) buffer (0.04 M Tris, 0.001 M EDTA, 0.02 M acetic acid) at 160 V on a 0.8 % 
agarose gel supplemented with intercalater EtBr.  
 
Table 1: Primer Sequences for Mutagenic PCR Amplification 
 
 
Small-Scale Expression of ArnD Mutants: Similar to the transformation procedure in XL-10 cells heat 
shock was used in order to uptake the mutated plasmid. A mixture of 20 µL BL-21 Rosetta cells (Novagen) 
and 1 µL of purified plasmid DNA was incubated on ice for 30 min, then heated for 30 sec at 42°C, and last 
incubated 2 min on ice. After 180 uL of LB broth containing 50 µg/ml kanamycin was added, the cells 
were incubated for 1 hour in a 37°C shaker and the 200 µL was plated on an LB selective growth plate 
supplemented with 50 µg/mL kanamycin. The plate was incubated overnight at 37°C. After colonial 
growth, a single colony was inoculated in ~4 mL LB broth supplemented with 50 µg/mL kanamycin, grown 
in a 37°C shaker to an OD600 of ~0.6, and cooled on ice for 10 min. Prior to expression a 20 µL aliquot was 
taken for SDS-PAGE analyzation.  Expression was induced by the addition of 0.5 mM isopropyl-β-D-
thiogalactopyranoside (IPTG, Gold Bio Technology Inc.), and cultures were allowed to grow overnight in a 
20°C shaker. After induction, the remaining 180 µL aliquot was centrifuged at 13,000 rpm for 10 min, the 
supernatant was removed, and the pellet was resuspended in 20 µL of MilliQ ddH2O.  
 
Large Scale Expression & Purification of ArnD Mutants: The following procedure was preformed 
independently for all 5 mutants:  
A mixture of 20 µL BL-21 Rosetta cells (Novagen) and 1 µL of purified mutated plasmid DNA was 
incubated on ice for 30 min, then heated for 30 sec at 42°C, and last incubated 2 min on ice. After, 180 uL 
of LB broth containing 100µg/ml kanamycin was added, the cells were incubated for 1 hour in a 37°C 
shaker and the 200 µL was plated on an LB selective growth plate supplemented with 50 µg/mL 
Mutation Primer Sequences (mutant codons are bold and underlined, coding strands are presented 
above non-coding strands, all strands written 5’-3’) 
D43N 5’-GCT TTT TCT TCA GCG TCG GGC CGA ACA ATA TTG GAC GTC ATC TTT GG-3’ 
5’-CCA AAG ATG ACG TCC CAT ATT GTT CGG CCC GAC GCT GAA GAA AAA GC-3’ 
D43S 5’-GCT TTT TCT TCA GCG TCG GGC CGA GCA ATA TTG GAC GTC ATC TTT GG-3’ 
5’-CCA AAG ATG ACG TCC CAT ATT GCT CGG CCC GAC GCT GAA GAA AAA GC-3’ 
H233W 
 
5’-GCA CGC CGG TAT ATA CCA TCT GGG CGG AAG TCG AAG GTA TTG TCC-3’ 
5’-GGA CAA TAC CTT CGA CTT CCG CCC AGA TGG TAT ATA CCG GCG TGC-3’ 
H233Y 5’-GCA CGC CGG TAT ATA CCA TCT ATG CGG AAG TCG AAG GTA TTG TCC-3’ 
5’-GGA CAA TAC CTT CGA CTT CCG CAT AGA TGG TAT ATA CCG GCG TGC-3’ 
H233R 5’-GCA CGC CGG TAT ATA CCA TCC GTG CGG AAG TCG AAG GTA TTG TCC-3’ 
5’-GGA CAA TAC CTT CGA CTT CCG CAC GGA TGG TAT ATA CCG GCG TGC-3’ 
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Kanamycin. The plate was incubated overnight at 37°C. After colonial growth, a single colony was 
inoculated in ~4 mL LB broth supplemented with 50 µg/mL Kanamycin, grown in a 37°C shaker to an 
OD600 of ~0.6, and cooled on ice for 10 min. This mixture was subsequently mixed in equal parts with 
100% glycerol to obtain a 50% glycerol stock and stored at -70° C for further experimentation. 
Subsequently, each mutant was grown independently in 65 mL LB broth supplemented with 50 µg/mL 
Kanamycin by addition of a small amount (~ >1 µL) of 50% glyerol cell culture. This culture was 
incubated overnight at 37°C, then 10 mL of the overnight culture was used to inoculate 6 x 1 L LB broth 
flasks supplemented with 50 µg/mL Kanamycin. These cultures were incubated at 37°C to an OD600 of 
~0.6, and cooled on ice for 30 min. A 1 mL aliquot was removed and labeled Before Expression (B). 
Expression was induced by the addition of 0.5 mM IPTG to each of the 6 x 1 L cultures. Expression 
proceeded overnight at Room Temperature (RT) ~20° C. A 0.5 mL aliquot was removed and labeled After 
Expression (A).Cells were then harvested by means of centrifugation at 5,000 RPM for 30 min. at 4° C.  
The cell pellet was resuspended in buffer containing: 25 mM Tris-HCl at pH 8.0, 300 mM NaCl , 5 mM 
BME, 10% Glycerol, and complete EDTA-free protease inhibitor cocktail (Roche) used at 1 tablet per 100 
mL of buffer. Cells were lysed by use of French Press at a 1000 PSI. A 20 µL aliquot was removed and 
labeled Lysis (L). Excess cell debris was removed from the cell lysis by use of a low-speed centrifugation 
at 15,000xg for 30 min at 4° C. After centrifugation, a 20 µL aliquot of supernatant was removed and 
labeled total protein, containing both the soluble and membrane proteins (T). The supernatant was then 
removed for ultra-centrifugation at 40,000 RPM for 3 Hrs at 4° C. After ultra-centrifugation, a 20 µL 
aliquot of the supernatant was removed and labeled soluble protein (S). The pellet was then removed and 
dissolved in resuspension buffer containing: 25 mM Tris-HCl at pH 8.0, 300 mM NaCl , 5 mM BME, 10% 
Glycerol,  1% Triton X-100 (Sigma). A 20 µL aliquot of the dissolved pellet was removed and labeled total 
membrane fraction (M1).  A high-speed centrifugation was then preformed at 40,000 x g for 30 min at 4° C 
to remove all undissolved particles. A 20 µL aliquot of the supernatant was removed and labeled actual 
membrane fraction (M2). The supernatant was further purified by use of a ~10 mL Ni-NTA agarose 
column (Qiagen) pre-equilibrated with: 25 mM Tris-HCl at pH 8.0, 300 mM NaCl, 5 mM BME, 10% 
Glycerol,  1% Triton X-100. ~4 column volumes of M2, membrane protein supernatant, was added to the 
column (F). The column was then washed to dissociate non-specific binding of undesired proteins first by 
running ~4.5 column volumes of: 25 mM Tris-HCl at pH 8.0, 300 mM NaCl, 5 mM BME, 10% Glycerol,  
0.1% Triton X-100, and 15 mM imidazole (W1). Next, a second wash was performed to exchange the 
detergent surrounding ArnD by running ~4.5 column volumes of: 25 mM Tris-HCl at pH 8.0, 150 mM 
NaCl, 5 mM BME, 10% Glycerol , 0.0435% or x5 CMC DDM, and 15 mM imidazole (W2). ArnD was 
eluted by running ~3.5 column volumes of: 25 mM Tris-HCl at pH 8.0 , 300 mM NaCl, 5 mM BME, 10% 
Glycerol,  0.0435% or x5 CMC DDM, and 300 mM imidazole (E). This eluted sample of ~35 mL was 
concentrated to ~5mL using a 50 KDa MWCO concentrator, and then the concentrated protein was further 
purified by use of a S200 size exclusion chromatography. The sample was first filtered through 0.20 µm 
nylon syringe filter, and next loaded on HiLoad 26/60 Superdex 200 Prep Grade Column (Amersham 
Pharmacia Biotech) pre-equilibrated with: 25 mM Tris-HCl at pH 8.0, 300 mM NaCl, 5 mM BME, 10% 
Glycerol,  0.1% Triton X-100, and 15 mM imidazole. In an identical buffer the enzyme was eluted into 4 
mL fractions measuring absorbance by use of a spectrophotometer at 280 nm. These fractions as well as 
aliquoted portions along the purification process were analyzed via SDS PAGE. The fractions containing 
purified protein were pooled and concentrated using a 50 KDa MWCO concentrator, the total protein 
concentration was determined by a Lowry assay. The purified protein was stored at -70° C until further 
experimentation. 
 
Sodium-Dodecyl- Sulfate Polyacrilamide Gel Electrophoresis (SDS PAGE): The following gel was made 
for the analysis of all protein samples: ~7.5 mL running gel: 12% Acrylamide mix, Tris-HCl, pH 8.8, 0.1% 
SDS, 0.1% Ammonium Persulfate (APS), 0.003 mL TEMED, 2.475 mL ddH20; ~1mL Stacking Gel: 5% 
Acrylamide mix, Tris-HCl, pH 6.5, 0.1% SDS, 0.1% Ammonium Persulfate (APS), 0.001 mL TEMED, 
0.68 mL ddH20. 5 uL of protein ladder was added to one lane while 10 uL of sample was added to the 
other various wells. The gel was ran for ~1 Hr at a constant voltage of 150V. The gel was then stained for 
~1Hr in 50% MeOH 10% Acetic Acid and 0.25% Brilliant Blue R-250 and then destained in ddH20. 
 
Lowry Assay: First, x20, x50, x200 dilutions were made of the purified WT ArnD as well as the various 5 
mutant constructs. Then using Bovine Serum Albumin (BSA) 400 mg/mL, 300 mg/mL, 200 mg/mL, 100 
mg/mL, 50 mg/mL and 0 mg/mL concentrations were made in order to form a standard curve. Pipette the 
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various samples into ependorfs and add 1mL ddH20. Then add 150 uL 1% Deoxycholate in .1 M NaOH, 
mix and incubate at RT for 5 min. Add 200 uL 50% TCA, mix and incubate on ice for 15 min, spin down 
the precipitate in micro fuge 14,000 RPM for 10 min. Pipette off supernatant and add 1.15 mL of dilutent 
mixture containing: 19.6 mL of  2% Na2CO3 in water, 200 µL of 1% CiSo4•5H2O in water, and 200 µL 
1%KNa Tartate•45H2O in water. Vortex until resuspended, incubate at RT for 10 min. Add 200 µL of 
dilute 1:1 Folin-Ciocalteau reagent with ddH2O and incubate in the dark for ~1 hour. Measure the 
Absorbance at 750nm. Use the BSA to form a line of best fit then by using the slope the concentration of 
unknown enzyme can be obtained. 
 
ArnD Substrate Formation:  The following reaction sequence was incubated in order to produce the 
product of ArnD, enzymatically, with radiolabeled UDP-Glucuronic acid as the substrate. First: 50 mM 
HEPES, 0.5 mg/mL ArnA-CTD, 2 mM DTT, 3mM NAD, 0.8 µM *UDP-Glucuronic Acid, was incubated 
overnight. Following the first incubation 1mM L-Glutamate and 0.5 mg/mL ArnB was added to the 
reaction mixture and incubated overnight. Next, 0.5 mg/mL Full length ArnA was added along with 1 mM 
N-10-metyltetrahydrofolate produced as explained in [31]. 11 µL of this entire mixture of product and 
reactants along with the accompanying enzymes was then separated and pipetted into a reaction tube 
containing 2 µL 1% Triton-X-100, 2 µL 500 mM HEPES pH7.5, 2 mM Mn2+, and 0.5 mg/mL purified 
ArnC, in previously evaporated Undecaprenyl Phosphate (Polish Academy of Sciences) with ddH2O to 
make a final volume of 20 µL. Formation of a product was confirmed by TLC, where a signal was shown 
that subsequently migrated after the addition of 0.05 mg/mL purified ArnD. 
 
WT ArnD Activity Analysis: In order to measure the activity of ArnD various concentrations were used of 
ArnD were added to the reactant mixture of ArnC product with the simultaneous addition of 2 µL of 5 mM 
CoCl2. The three concentrations of ArnD shown are 0.05, 0.005 and 0.001 mg/mL, respectively. These 
reactions were ran for 48 min taking and plating 2 µL aliquots at the time pints 8 min, 16 min, 24 min, 48 
min.  
 
Mutant ArnD Activity Analysis: In order to measure the activity of mutant ArnD constructs, identical assays 
were performed as above in WT Activity Analysis. 0.05 mg/mL concentrations of ArnD mutants were 
added to the reactant mixture of ArnC product with the simultaneous addition of 2 µL of 5 mM CoCl2. . 
These reactions were ran for 48 min taking and plating 2 µL aliquots at the time pints 8 min, 16 min, 24 
min, 48 min.  
 
TLC Analysis: Two separate assays were performed: 
• A PEI Cellulose Plate (EMD Chemicals) was first soaked in methanol and dried. Next, the plate 
was spotted by: UDP-glucuronic acid, UDP-4-keto-glucuronic acid, UDP-4-ketopentose UDP-4-
aminoarabinose (UDP-β-L-Ara4N), and Ara4N-formyl (UDP-β-L-Ara4FN). The solvent used 
was: 0.4 M LiCl (Sigma), 0.25 M Acetic Acid (Mallinckrodt Chemicals).  
• A TLC Silica Gel 60 F254 plate (EMD Chemicals) was spotted by: UDP-β-L-Ara4FN, 
undecaprenyl-phosphate-L-Ara4FN, undecaprenyl-phosphate-L-Ara4N. The solvent used was 
(64/24/3.6/.4) (CHCl3/MeOH/H2O/NH4SO4 (Mallinckrodt Chemicals, Fischer Scientific). 
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